Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy [2]

Pediatric Nephrology

Volumn 17, Issue 4, 2002, Pages 302-304

  Bhattacharjee, Rakesh ^a   Filler, Guido ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

ACE inhibitors; Angiotensin II receptor antagonists; IgA nephropathy; Losartan; Proteinuria

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CATHEPSIN G; CHYMASE; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LOSARTAN; PREDNISOLONE; PREDNISONE; SERINE PROTEINASE; SERUM ALBUMIN; TONIN; WARFARIN;

ADULT; BLOOD PRESSURE MEASUREMENT; CHILD; COUGHING; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DRUG POTENTIATION; DRUG SAFETY; FOLLOW UP; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; LETTER; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT WITHDRAWAL; URINARY EXCRETION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG SYNERGISM; GLOMERULONEPHRITIS, IGA; HUMANS; LOSARTAN; PROTEINURIA;

EID: 0036952930     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-002-0829-y     Document Type: Letter

References (11)

1. Yoshikawa N, Tanaka R, Iijima K (2001) Pathophysiology and treatment of IgA nephropathy in children [review]. Pediatr Nephrol 16:446-457
2. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R (1999) Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33: 851-856
3. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM (2001) Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38:18-25
4. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL (1995) Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 123:754-762
5. Cattran DC, Greenwood C, Ritchie S (1994) Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23:247-254
6. Mento PF, Wilkes BM (1987) Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 9:III42-48
7. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H (1982) Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4:966-972
8. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A (1993) Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 91:1269-1281
9. Phillips MI, Speakman EA, Kimura B (1993) Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 43:1-20
10. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA (1995) Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 43:84-88
11. Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M (1999) A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 10:101-109